Modeling tumor development and progression: From PDXs to cancer organoids | A colloquium sponsored by SIRIC ILIAD
On October 18th, the French PDX network and the Organoids research group organised, with the support of the SIRIC ILIAD
Breast cancers: acting on cells in the tumour environment to treat the cancer?
What if acting on the cells surrounding the tumour could improve the effectiveness of treatments? On 14 September 2022, a
SIRIC ILIAD shares its research progress with its partners | SIRIC Review 2018-2022
The SIRIC ILIAD Partners Committee met on Monday 17 October 2022 to present the results of the 5 years of
Teclistamab: a promising new treatment for multiple myeloma
Last August, Professor Philippe Moreau, haematologist and director of SIRIC ILIAD, published a scientific article in the prestigious New England
Welcome to Sara Gandolfi, post-doctoral researcher in cell biology at SIRIC ILIAD!
Since May 2022, Sara Gandolfi has joined the ranks of the SIRIC ILIAD teams as a post-doctoral researcher. She has
Immunotherapy in multiple myeloma: focus on bispecific antibodies
Last June, Professors Philippe Moreau and Cyrille Touzeau, both haematologists and researchers at SIRIC ILIAD, published a scientific article in
Opening for a postdoctoral position at the CRCI²NA
The Centre de Recherches en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI²NA) offers a postdoctoral position in cell biology. Contract
In 2022, the CRCINA evolves and becomes the CRCI²NA
In January 2022, at the end of its five-year mandate, the CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes
“This protected medical time supported by the SIRIC allows me to make the link between the clinic and the research laboratories, so that the results obtained are linked to the medical reality of the patients. – Jean-Sébastien Frenel
Doctor Jean-Sébastien Frenel, an oncologist at the Institut de Cancérologie de l’Ouest, has benefited from “protected medical time” since 1
Cancer research: The importance of SIRICs recognised by the scientific committee of INCa
Following the mid-term evaluation of the SIRICs (SIte de Recherche Intégrée sur le Cancer), the scientific committee of the French
